News
NVTA
2.290
-9.13%
-0.230
Hims & Hers Health, Inc. (HIMS) Reports Q2 Loss, Tops Revenue Estimates
Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of 0% and 11.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 1d ago
Earnings Outlook For Invitae
  Invitae (NYSE:NVTA) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement. Analysts estimate that Invitae will report an earnings per share (EPS) of $-0.76.
Benzinga · 1d ago
New NCCN Colorectal Cancer Guidelines Recommend Genetic Testing for All Diagnosed Patients
As a result of recent research revealing that a significant number of colorectal cancer patients with actionable variants are missed under previous genetic testing guidelines, the National Comprehensive Cancer Network (NCCN) announced new guidelines callin...
PR Newswire · 1d ago
IRhythm Technologies (IRTC) Reports Q2 Loss, Tops Revenue Estimates
iRhythm Technologies (IRTC) delivered earnings and revenue surprises of 15.96% and 2.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 5d ago
Top 10 Stock Picks of Eli Casdin’s Casdin Capital
In this article, we discuss the top 10 stock picks of Eli Casdin’s Casdin Capital. If you want to skip our detailed analysis of Casdin’s investment philosophy and performance, go directly to Top 5 Stock Picks of Eli Casdin’s Casdin Capital. Eli Casdin foun...
Insider Monkey · 08/02 13:11
Invitae to Announce Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its second quarter 2022 financial results on Tuesday, August 9, 2022, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacifi...
PR Newswire · 08/02 11:00
Analysts Estimate 1Life Healthcare, Inc. (ONEM) to Report a Decline in Earnings: What to Look Out for
1Life Healthcare, Inc. (ONEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/27 14:02
Sector Update: Health Care Stocks Hang on for Small Gains
Sector Update: Health Care Stocks Hang on for Small Gains
MT Newswires · 07/26 16:25
Invitae downgraded to market perform at Cowen on timing uncertainty for debt refinancing
Cowen has downgraded Invitae (NYSE:NVTA) to market perform fr...
Seekingalpha · 07/26 15:14
Will Invitae (NVTA) Report Negative Q2 Earnings? What You Should Know
Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/26 14:01
--Cowen Downgrades Invitae to Market Perform From Outperform, Adjusts Price Target to $2.50 From $8
--Cowen Downgrades Invitae to Market Perform From Outperform, Adjusts Price Target to $2.50 From $8
MT Newswires · 07/26 06:07
Analysts Just Revised Their Ratings for These 10 Stocks
In this article, we will take a look at analysts’ revised recommendations for 10 companies. If you want to see some other companies that received ratings change from analysts, go directly to Analysts Just Revised Their Ratings for These 5 Stocks. Analysts ...
Insider Monkey · 07/21 22:45
This Analyst Says Invitae's Current Valuation 'Not Accommodative'
Benzinga · 07/21 19:28
Invitae stock rises despite getting cut to Market Perform at Raymond James
Invitae (NYSE:NVTA) stock was in the green (<font color="gree...
Seekingalpha · 07/21 16:24
--Raymond James Downgrades Invitae to Market Perform From Outperform
MT Newswires · 07/21 07:21
Invitae down 16% as investors take in new CEO, 2022 revenue guidance, and restructuring
Invitae (NYSE:NVTA) shares are down 16%</fo...
Seekingalpha · 07/19 19:16
Invitae slumps 17%, rating remained cut by SVB Securities and Benchmark
Invitae (NYSE:NVTA) downgraded to Marketperform from Outperform at S...
Seekingalpha · 07/19 19:13
Hot Stocks: NCR rises on deal report; SI jumps on earnings; CNK upgrade; NVTA restructuring
A potential M&amp;A deal took a share of the spotlight in Tuesday's midday trading. NCR (NYSE:<a href="https://seekingalpha.com/symbol/NCR?utm_medium=referral&utm_source=webull.com" title="NCR Corporation" target="_bla...
Seekingalpha · 07/19 16:32
Invitae (NVTA) Stock Falls 12% on Cost-Cutting Plan
Investor Place · 07/19 16:13
Apellis, Neuronetics top healthcare gainers; High Tide, Ultragenyx lead losers' pack
Gainers: Apellis Pharmaceuticals (APLS) +22%. Neuronetics ...
Seekingalpha · 07/19 14:00
More
Webull provides a variety of real-time NVTA stock news. You can receive the latest news about Invitae Corp through multiple platforms. This information may help you make smarter investment decisions.
About NVTA
Invitae Corporation is a medical genetics company. The Company is engaged in delivering genetic testing services that support a lifetime of patient care from inherited disease diagnoses, to family planning, to proactive health screening to personalized diagnosis, treatment and monitoring of cancer. These tests are delivered through a platform that serves patients, healthcare providers, biopharma companies and other partners, thereby capturing the potential of genetics and helping to expand its use across the healthcare continuum. It offers Invitae Digital Health, a connected digital health platform that informs health decisions through actionable genomic insights for patients and clinicians. The Company offers genetic testing across multiple clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, personalized oncology, metabolic conditions, and rare diseases.